Cancer Biother Radiopharm 2008, 23:477–482.PubMedCrossRef 13. Jakab F, Shoenfeld Y, Balogh A, Nichelatti M, Hoffmann A, Kahan Z, Lapis K, Mayer A, Sapy P, Szentpetery F, Telekes A, Thurzo L, Vagvolgyi A, Hidvegi M: A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer 2003, 89:465–469.PubMedCrossRef 14. Pfeiffer B, Preiß J, Unger C: Avemar. Onkologie integrativ, Urban & Fischer Verlag München; 2006:226–229. 15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New BIBW2992 cell line colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer
Inst 1990, 82:1107–1112.PubMedCrossRef 16. Drewinko B, Dipasquale MA, Yang LY, Barlogie B, Trujillo JM: The synergistic lethal interaction of cis-diamminedichloroplatinum and natural nucleosides is related to increased DNA cross-links. Chem Biol Interact 1985, 55:1–12.PubMedCrossRef 17. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato BMS202 purchase K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N: In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res 1989, 49:4098–4102.PubMed 18. Berger DP, Henss H, Winterhalter BR, Fiebig HH: The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening.
Ann Oncol 1990, 1:333–341.PubMed 19. Schroyens W, Tueni E, Dodion P, Bodecker R, Stoessel F, Klastersky J: Validation of clinical predictive value of in vitro colorimetric Resminostat chemosensitivity assay in head and neck cancer. Eur J Cancer 1990, 26:834–838.PubMedCrossRef 20. Voigt W, Bulankin A, Muller T, Schoeber C, Grothey A, Hoang-Vu C, Schmoll HJ: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000, 6:2087–2093.PubMed 21. Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A: The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment.
Cancer Biother Radiopharm 2004, 19:746–753.PubMedCrossRef 22. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A: Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5):v70–77. 23. Szende B, Marcsek Z, Kocsis Z, Tompa A: Effect of simultaneous administration of Avemar and cytostatic drugs on viability of cell cultures, growth of experimental tumors, and survival tumor-bearing mice. Cancer Biother Radiopharm 2004, 19:343–349.PubMedCrossRef Competing interests The authors declare that they have no competing interests.”
“1. Introduction Cancer is one of the main causes of death among Westernized countries and is principally due to environmental risk factors, www.selleckchem.com/products/bay-11-7082-bay-11-7821.html including diet [1].